PDCD1 and cervical carcinoma: The Phase III, multicenter, open-label trial EMPOWER Cervical 1/GOG-3016/ENGOT-cx9 evaluated the efficacy of the anti-PD-1 antibody cemiplimab in patients with cervical cancer who progressed after first-line platinum-based chemotherapy [88].